Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers
Sponsor: Beijing QL Biopharmaceutical Co.,Ltd
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) parts.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT003 Injection in Healthy Volunteers and Overweight or Obese Volunteers
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2025-10-16
Completion Date
2026-10-10
Last Updated
2026-01-30
Healthy Volunteers
Yes
Conditions
Interventions
ZT003
ZT003 is administered as a single subcutaneous injection at different dose levels.
ZT003
ZT003 administered as multiple subcutaneous injections at different dose levels.
Placebo
Matching placebo administered subcutaneously.
Locations (1)
Nucleus Network Brisbane
Brisbane, Queensland, Australia